Tag: tsx:imv

November 2, 2018

IMV Announces Q3 2018 Financial Results

IMV (Nasdaq:IMV;TSX:IMV), a clinical stage immuno-oncology corporation, today released its financial and operational results for the three- and nine-month period...
October 3, 2018

VIDEO — Life Science Update September 2018

With September officially behind us, the Investing News Network is taking a look back at some of the biggest news...
September 11, 2018

Merck and IMV Form Oncology Collaboration

For some, Merck’s cancer drug Keytruda may seem like one of the most developed drugs, with multiple US Food and...
September 11, 2018

IMV Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA Across Five Solid Tumor Indications

IMV (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today announced that it has expanded its clinical program with a Phase...